• Profile

A randomized, double‐blind, multi‐center, placebo‐controlled, phase 2 clinical trial to evaluate the efficacy and safety of DWJ211 in the treatment of moderate to severe submental fat

Dermatologic Therapy Feb 15, 2022

In this study, 1% DWJ211 dose (a newly developed lipolytic injectable) was proven to be beneficial for submental fat (SMF) reduction and demonstrated a tolerable safety profile. Therefore, 1% was chosen as the dose to be investigated in a phase 3 clinical trial.

  • This is a multi-center, double-blind, placebo-controlled study including 136 persons with moderate to severe SMF who were randomly assigned to injections of DWJ211 0.5%, DWJ211 1%, DWJ211 2% or placebo in the submental area, every 4 weeks, up to week 12.

  • In the placebo, DWJ211 0.5%, DWJ211 1%, and DWJ211 2% groups, ≥1-grade improvement on the physician-assisted SMF rating scales was achieved by 41.7%, 65.7%, 84.4%, and 72.7% of the patients, respectively, and ≥1-grade improvement on the subject-assisted SMF rating scales was achieved by 50.0%, 71.4%, 93.8%, and 81.8%, respectively.

  • In each of the treatment groups, adverse drug reactions (ADRs) were more common, relative to placebo, with injection site pain being the most common ADR.

  • Serious adverse events were not observed.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen